IL156910A0 - Isolating cells expressing secreted proteins - Google Patents

Isolating cells expressing secreted proteins

Info

Publication number
IL156910A0
IL156910A0 IL15691002A IL15691002A IL156910A0 IL 156910 A0 IL156910 A0 IL 156910A0 IL 15691002 A IL15691002 A IL 15691002A IL 15691002 A IL15691002 A IL 15691002A IL 156910 A0 IL156910 A0 IL 156910A0
Authority
IL
Israel
Prior art keywords
poi
isolating cells
cells expressing
secreted proteins
expressing secreted
Prior art date
Application number
IL15691002A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL156910A0 publication Critical patent/IL156910A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL15691002A 2001-01-16 2002-01-16 Isolating cells expressing secreted proteins IL156910A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26199901P 2001-01-16 2001-01-16
PCT/US2002/001208 WO2002057423A2 (en) 2001-01-16 2002-01-16 Isolating cells expressing secreted proteins

Publications (1)

Publication Number Publication Date
IL156910A0 true IL156910A0 (en) 2004-02-08

Family

ID=22995765

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15691002A IL156910A0 (en) 2001-01-16 2002-01-16 Isolating cells expressing secreted proteins
IL156910A IL156910A (en) 2001-01-16 2003-07-14 Method of detecting and isolating eukaryotic cell that produces secreted protein of interest

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156910A IL156910A (en) 2001-01-16 2003-07-14 Method of detecting and isolating eukaryotic cell that produces secreted protein of interest

Country Status (10)

Country Link
US (3) US6919183B2 (de)
EP (1) EP1392859B1 (de)
JP (1) JP4323167B2 (de)
AT (1) ATE325865T1 (de)
AU (1) AU2002245272B2 (de)
CA (1) CA2434802C (de)
DE (1) DE60211329T2 (de)
HK (1) HK1059290A1 (de)
IL (2) IL156910A0 (de)
WO (1) WO2002057423A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
EP1392859B1 (de) * 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
GB0118337D0 (en) * 2001-07-27 2001-09-19 Lonza Biologics Plc Method for selecting antibody expressing cells
NZ552851A (en) * 2002-05-22 2008-09-26 Biogen Idec Inc Detection of a secreted polypeptide on the surface of a cell used as a marker for cellular productivity of the secreted polypeptide
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7771969B2 (en) 2003-08-20 2010-08-10 Celltech R&D Limited Methods for obtaining antibodies
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
JP2009535063A (ja) 2006-05-04 2009-10-01 アブマクシス・インコーポレイテツド 異種間及び複数種提示系
EP2208792B1 (de) 2006-05-17 2015-05-06 Hoffmann-La Roche AG Polypeptide produzierende Zellen
US8067179B2 (en) 2006-11-30 2011-11-29 Research Development Foundation Immunoglobulin libraries
US8603950B2 (en) 2007-02-20 2013-12-10 Anaptysbio, Inc. Methods of generating libraries and uses thereof
WO2008118476A2 (en) 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
CA3187687A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
WO2009103753A1 (en) * 2008-02-20 2009-08-27 Ablynx Nv Methods for identifying and/or sorting cells by secreted molecule and kits for performing such methods
JP5731827B2 (ja) 2008-03-03 2015-06-10 グライコフィ， インコーポレイテッド 下等真核生物中での組換えタンパク質の表面ディスプレイ
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
WO2010064748A1 (en) 2008-12-04 2010-06-10 Korea Research Institute Of Bioscience And Biotechnology Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins
ES2661074T3 (es) 2009-06-02 2018-03-27 Regeneron Pharmaceuticals, Inc. Células deficientes de fucosilación
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8278873B2 (en) * 2009-09-10 2012-10-02 Syntheon, Llc Surgical sterilizer with integrated battery charging device
CA2789446A1 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
EP2390661B1 (de) 2010-05-02 2015-06-24 Miltenyi Biotec GmbH Verankerungs-/Erfassungsmittel zum Auswählen oder Analysieren einer CHO-Zelle entsprechend einem Produkt, das von der CHO-Zelle sezerniert wird
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
KR101291241B1 (ko) 2010-11-04 2013-08-01 한국생명공학연구원 효모에서 인체 상피세포 성장인자를 대량 생산하는 방법
IL210093A0 (en) * 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
JP2014504503A (ja) 2010-12-28 2014-02-24 ゾーマ テクノロジー リミテッド Ｐｄｚドメインを用いた細胞表面提示
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
CN103476777B (zh) 2011-01-31 2015-05-27 诺瓦提斯公司 新杂环衍生物
CN102680679B (zh) * 2011-03-15 2014-08-27 中国科学院上海生命科学研究院 检测单细胞特异性抗体分泌的细胞微孔芯片及其制备方法
PL2771342T3 (pl) 2011-10-28 2016-11-30 Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
US9890378B2 (en) 2012-05-11 2018-02-13 Merck Sharp & Dohme Corp. Surface anchored light chain bait antibody display system
RU2630975C2 (ru) 2012-05-16 2017-09-15 Новартис Аг Режим дозирования pi-3 киназы
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
CN109369808B (zh) 2012-08-24 2023-11-07 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
TWI675044B (zh) * 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EA201591700A1 (ru) 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
CN105637085A (zh) 2013-10-11 2016-06-01 瑞泽恩制药公司 代谢优化的细胞培养物
KR20160095035A (ko) 2013-12-06 2016-08-10 노파르티스 아게 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
MX2018005298A (es) 2015-11-02 2018-06-22 Novartis Ag Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
WO2017132701A1 (en) * 2016-01-31 2017-08-03 Shuang Zhang Method for screening antibodies
KR20180104149A (ko) 2016-02-04 2018-09-19 트리아니, 인코포레이티드 면역글로불린의 증대된 생성
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
EP3464332A1 (de) 2016-05-26 2019-04-10 University College Cork - National University of Ireland, Cork Verfahren zur erhöhung der proliferation von säugetierzellen
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
WO2018041740A1 (en) 2016-09-01 2018-03-08 Bayer Pharma Aktiengesellschaft Non-covalent display system using fimgt/dsf
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
JP6818134B2 (ja) 2016-09-29 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド産生細胞を選択するための改善された方法
GB201703418D0 (en) 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
GB201704115D0 (en) * 2017-03-15 2017-04-26 Oxford Genetics Ltd Method of selecting for antibodies
JP7287940B2 (ja) * 2017-03-24 2023-06-06 ランケナウ・インスティテュート・フォー・メディカル・リサーチ ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物
EP3673044A1 (de) 2017-08-25 2020-07-01 University College Cork-National University of Ireland, Cork Bifidobacterium longum zur behandlung von adipositas und gewichtskontrolle
WO2019102018A2 (en) 2017-11-24 2019-05-31 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
EP3604507A1 (de) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork Omega-transaminase-enzym
WO2020056456A1 (en) * 2018-09-17 2020-03-26 South Australian Health And Medical Research Institute Limited Methods for producing proteins
MX2021011956A (es) * 2019-04-03 2021-12-15 Regeneron Pharma Metodos y composiciones para la insercion de secuencias codificantes de anticuerpos en un locus de puerto seguro.
EP3783012A1 (de) 2019-08-20 2021-02-24 Nuritas Limited Antimikrobielles peptid
AU2020334196A1 (en) 2019-08-20 2022-03-03 Nuritas Limited Peptides for treating muscle atrophy
JP2022553367A (ja) 2019-10-22 2022-12-22 ニューリタス リミテッド 非アルコール性脂肪肝の治療
JPWO2022190733A1 (de) * 2021-03-10 2022-09-15
EP4070670A1 (de) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 und verwendungen davon
JP2024514195A (ja) 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 脳血管イベントおよび神経障害の治療
CA3214579A1 (en) 2021-04-14 2022-10-20 Tom Moore Psg1 for use in the treatment of osteoarthritis
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CN118076885A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH计校准与校正
WO2023167863A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
WO2024078729A1 (en) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury
CN118006552A (zh) * 2024-04-09 2024-05-10 暨南大学 一种抗原特异性浆细胞的筛选方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE237808T1 (de) * 1992-10-21 2003-05-15 Stefan Miltenyi Direkte auswahl von zellen durch ein aussheidungsprodukt
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
CA2330678C (en) 1998-05-11 2009-04-07 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE19900635A1 (de) * 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
EP1392859B1 (de) * 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen

Also Published As

Publication number Publication date
JP4323167B2 (ja) 2009-09-02
US7435553B2 (en) 2008-10-14
JP2004520037A (ja) 2004-07-08
ATE325865T1 (de) 2006-06-15
US20050186623A1 (en) 2005-08-25
WO2002057423A2 (en) 2002-07-25
AU2002245272B2 (en) 2006-06-29
EP1392859A2 (de) 2004-03-03
HK1059290A1 (en) 2004-06-25
CA2434802A1 (en) 2002-07-25
WO2002057423A3 (en) 2003-12-18
US6919183B2 (en) 2005-07-19
EP1392859B1 (de) 2006-05-10
DE60211329D1 (de) 2006-06-14
DE60211329T2 (de) 2007-05-24
IL156910A (en) 2009-08-03
US20060234311A1 (en) 2006-10-19
CA2434802C (en) 2013-05-28
US20020168702A1 (en) 2002-11-14
EP1392859A4 (de) 2004-11-24

Similar Documents

Publication Publication Date Title
HK1059290A1 (en) Isolating cells expressing secreted proteins
WO2002034906A3 (de) Verfahren zur exposition von peptiden und polypeptiden auf der zelloberfläche von bakterien
WO2003068947A8 (en) Assay electrodes having immobilized lipid/protein layers and methods of making and using the same
WO2002079490A3 (en) Bio-barcodes based on oligonucleotide-modified particles
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
WO2002004523A3 (en) Artificial antibody polypeptides
EP1499885A4 (de) Neue fusionsproteine und molekulare bindungsassays
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
WO2006107813A3 (en) Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-trna synthetase
DK1616878T3 (da) Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
WO2002086081A3 (en) Methods and systems for identifying proteins
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
WO1999009179A3 (en) Antigen constructs useful in the detection and differentiation of antibodies to hiv
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides
DK1576157T3 (da) Fluorescerende proteiner fra Copepode-arter og fremgangsmåder til anvendelse af samme
WO2003018797A3 (en) Method and device for integrated protein expression, purification and detection
WO2003016904A3 (en) Peptide sequence tags and method of using same
ATE310248T1 (de) Biomolekülanalyse auf array-basis
WO2002064747A3 (en) Fusion proteins based upon somatostatin receptors
WO2003062444A3 (en) Array systems and methods
WO2003033650A3 (en) Recombinant renilla reniformis system for bioluminescence resonance energy transfer
HUP0101987A2 (hu) Antibiotikus hatású proteinek és peptidek indukciója LAIT/sCD14-proteinnel
ATE307142T1 (de) Zweifarbiges fluorimetrisches proteaseassay
DE60216721D1 (de) Verfahren zum Nachweis von Protein-Proteininteraktionen in Membranen
WO2002081523A3 (fr) Procede de preparation et de selection d'anticorps